Sei Investments Co. Grows Position in Omnicell, Inc. $OMCL

Sei Investments Co. raised its stake in Omnicell, Inc. (NASDAQ:OMCL) by 21.1% in the first quarter, HoldingsChannel.com reports. The fund owned 148,394 shares of the company’s stock after purchasing an additional 25,899 shares during the quarter. Sei Investments Co.’s holdings in Omnicell were worth $4,953,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Dana Investment Advisors Inc. acquired a new stake in shares of Omnicell during the 4th quarter worth about $3,445,000. Universal Beteiligungs und Servicegesellschaft mbH raised its position in shares of Omnicell by 71.1% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 140,032 shares of the company’s stock valued at $6,343,000 after buying an additional 58,193 shares during the last quarter. Peregrine Capital Management LLC purchased a new position in shares of Omnicell during the fourth quarter valued at approximately $4,804,000. Teachers Retirement System of The State of Kentucky boosted its position in Omnicell by 96.3% during the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 25,914 shares of the company’s stock worth $1,174,000 after acquiring an additional 12,713 shares during the last quarter. Finally, Jackson Creek Investment Advisors LLC acquired a new stake in Omnicell during the fourth quarter worth approximately $2,022,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

OMCL has been the subject of several analyst reports. Weiss Ratings upgraded Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Zacks Research cut Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Piper Sandler reaffirmed an “overweight” rating and issued a $45.00 price objective (down from $55.00) on shares of Omnicell in a research report on Monday. Craig Hallum reiterated a “buy” rating and issued a $55.00 target price on shares of Omnicell in a research note on Wednesday, April 29th. Finally, Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Omnicell currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.86.

Omnicell Stock Up 0.1%

Shares of NASDAQ OMCL opened at $37.17 on Thursday. Omnicell, Inc. has a 52-week low of $29.06 and a 52-week high of $55.00. The firm has a fifty day moving average of $41.58 and a 200-day moving average of $40.73. The stock has a market capitalization of $1.69 billion, a PE ratio of 44.25, a P/E/G ratio of 1.01 and a beta of 0.98. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.47. The business had revenue of $312.21 million for the quarter, compared to analyst estimates of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The business’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period last year, the company posted $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, analysts anticipate that Omnicell, Inc. will post 1.31 EPS for the current year.

Insider Activity

In other news, EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $133,549.80. Following the transaction, the executive vice president directly owned 154,785 shares of the company’s stock, valued at $6,689,807.70. The trade was a 1.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $217,180.50. Following the sale, the executive vice president owned 112,783 shares of the company’s stock, valued at $4,874,481.26. The trade was a 4.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.92% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.